- Home
- » Tags
- » Gilead Sciences
Top View
- First Name Last Name Disclosure Enass Abdel-Hameed Nothing To
- Biogen and Gilead Top Tables with Most Valuable R&D Assets
- C.A. No. 2020-0132-KSJM ) GILEAD SCIENCES, INC., ) ) Defendant
- CSG Associates Entertainment Software Association Ewing Marion Kauffman Foundation 1-800 Contacts, Inc
- Vertex Pharmaceuticals Incorporated
- Faculty Disclosure
- Gilead Sciences Appoints Flavius Martin, MD As Executive Vice President, Research
- Case 1:15-Cv-00760-SLR Document 33 Filed 01/26/16 Page 1 of 18 Pageid #: 641
- Gilead Sciences Inc.: Roche's Daniel O'day to Be
- EMTRIVA® (Emtricitabine) Capsule, for Oral Use 200 Mg 200 Mg 200 Mg EMTRIVA® (Emtricitabine) Oral Solution Capsule 200 Mg Every Every Every Initial U.S
- J&J New Gilead Deal Could Spark Even More Combinations In
- Mylan Launches Gilead Sciences' Sovaldi® Tablets in India
- Faculty Disclosures
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
- Company Overview Gilead Sciences, Inc
- CFRI's Weekly Summary of News & Events for Our CF Community!
- Gilead Sciences
- Advancing Therapeutics. Improving Lives
- Mylan Secures Regulatory Approval for Remdesivir Lyophilized Powder for Injection 100 Mg/Vial in India for Restricted Emergency Use in COVID-19 Patients
- Report Relies on 10 Case Studies Drawn from a Variety of Nations, Technical Fields, and Firm Sizes
- JNJ Pipeline 1Q2017
- COVID-19: Issues Related to Vaccines and Treatment
- 4. Gilead Sciences V. Teva Pharmaceuticals
- Disclosures and Contributions
- HIGHLIGHTS of PRESCRIBING INFORMATION These Highlights Do Not Include All the Information Needed to Use SUSTIVA Safely and Effec
- 17A ___Merck & Co., Inc
- Gilead Sciences, Inc. Incoming Letter Dated December 21, 2018
- The Largest Pharmaceutical Companies Worldwide Analysis of Key Financial Indicators for Fiscal Years 2017, 2018 and 2019 About the Study
- Vertex Pharmaceuticals Incorporated (VRTX) Item 7 Friends Fiduciary Corporation Friends Fiduciary Corporation Seeks Your Support
- Faculty Disclosure
- In the United States District Court for the District of Delaware
- KPH Healthcare Services, Inc. V. Gilead Sciences
- Bristol-Myers Squibb and Gilead Sciences, LLC 1 Reference ID: 3691506 • Nursing Mothers: Women Infected with HIV Should Be Instructed Not to Breastfeed
- Biopharmaceutical Industry Pharmd Fellowships
- The Seven Habits of Highly Effective Competitors
- GILEAD SCIENCES, INC. V. MERCK &
- Faculty Disclosures
- Bristol-Myers Squibb Company & 11 E
- CFRI's Weekly Summary of News
- Faculty Disclosure
- Consensus Reports on Gilead Sciences, Inc. and Amgen Inc
- Abbvie Rival Gilead Makes Exclusive Deal with CVS for Hep C Drugs
- VEKLURY® (Remdesivir) for Injection
- US Corporate Overview 21915.Pdf
- CSG Leadership Circle Alexion Pharmaceuticals Alkermes Esri Everytown for Gun Safety HCA Healthcare Juul Labs Intuit Novo Nordis
- United States Securities and Exchange Commission Form
- Accelerating the Development of Covid-19 Vaccines and Therapeutics for Everyone
- Moderna 2020 Annual Report | 3 a Letter from Our CEO JANUARY 4, 2021 Cambridge, Mass., USA
- Gilead Sciences and Royalty Pharma Complete $525 Million Purchase from Emory University of Emtricitabine Royalty Interest
- COVID-19 R&D-Based Pharma Industry's Innovative Partnership To
- Third-Quarter Biotech Job Picture
- 1 Retreatment with Telaprevir Combination Therapy in Hepatitis C
- Digital Health Monitor – Pharmaceuticals
- Volunteer Disclosure Report